Cumulative Cancer Locations is a Novel Metric for Predicting Active Surveillance Outcomes: A Multicenter Study

Schröder, 2014, Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up, Lancet, 384, 2027, 10.1016/S0140-6736(14)60525-0 Loeb, 2014, Overdiagnosis and overtreatment of prostate cancer, Eur Urol, 65, 1046, 10.1016/j.eururo.2013.12.062 Klotz, 2015, Long-term follow-up of a large active surveillance cohort of patients with prostate cancer, J Clin Oncol, 33, 272, 10.1200/JCO.2014.55.1192 Bokhorst, 2016, A decade of active surveillance in the PRIAS study: an update and evaluation of the criteria used to recommend a switch to active treatment, Eur Urol, 70, 954, 10.1016/j.eururo.2016.06.007 Bruinsma, 2016, Active surveillance for prostate cancer: a narrative review of clinical guidelines, Nat Rev Urol, 13, 151, 10.1038/nrurol.2015.313 Hamdy, 2016, 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer, N Engl J Med, 375, 1415, 10.1056/NEJMoa1606220 Scattoni, 2007, Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature, Eur Urol, 52, 1309, 10.1016/j.eururo.2007.08.006 Lahdensuo, 2015, Performance of transrectal prostate biopsies in detecting tumours and implications for focal therapy, Scand J Urol, 49, 90, 10.3109/21681805.2014.936494 Bul, 2013, Active surveillance for low-risk prostate cancer worldwide: the PRIAS study, Eur Urol, 63, 597, 10.1016/j.eururo.2012.11.005 Vickers, 2006, Decision curve analysis: a novel method for evaluating prediction models, Med Decis Making, 26, 565, 10.1177/0272989X06295361 Amin, 2014, Arch Pathol Lab Med, 138, 1387, 10.5858/arpa.2014-0219-SA Ruijter, 1996, Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications, J Pathol, 180, 295, 10.1002/(SICI)1096-9896(199611)180:3<295::AID-PATH663>3.0.CO;2-W Häggman, 1997, Morphometric studies of intra-prostatic volume relationships in localized prostatic cancer, Br J Urol, 80, 612, 10.1046/j.1464-410X.1997.00409.x Han, 2012, Geometric evaluation of systematic transrectal ultrasound guided prostate biopsy, J Urol, 188, 2404, 10.1016/j.juro.2012.07.107 Iremashvili, 2013, Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models, BJU Int, 111, 574, 10.1111/j.1464-410X.2012.11127.x Helpap, 2016, Significance of number and localization of positive core biopsies for the identification of prostate cancer eligible for active surveillance, Anal Quant Cytopathol Histopathol, 38, 9 Mamawala, 2017, Risk prediction tool for grade re-classification in men with favourable-risk prostate cancer on active surveillance, BJU Int, 120, 25, 10.1111/bju.13608 Kim, 2013, Upgrading of Gleason score and prostate volume: a clinicopathological analysis, BJU Int, 111, 1310, 10.1111/j.1464-410X.2013.11799.x Tseng, 2011, Repeat prostate biopsies predict location of index cancer in an active surveillance cohort, BJU Int, 108, 1415, 10.1111/j.1464-410X.2011.10176.x Irshad, 2013, A molecular signature predictive of indolent prostate cancer, Sci Transl Med, 5, 10.1126/scitranslmed.3006408 Berg, 2014, ERG protein expression in diagnostic specimens is associated with increased risk of progression during active surveillance for prostate cancer, Eur Urol, 66, 851, 10.1016/j.eururo.2014.02.058 Lokman, 2017, PTEN loss but not ERG expression in diagnostic biopsies is associated with increased risk of progression and adverse surgical findings in men with prostate cancer on active surveillance, Eur Urol Focus, 68, 788 Loeb, 2015, Active surveillance for prostate cancer: a systematic review of clinicopathologic variables and biomarkers for risk stratification, Eur Urol, 67, 619, 10.1016/j.eururo.2014.10.010 Ahmed, 2017, Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study, Lancet, 389, 815, 10.1016/S0140-6736(16)32401-1 Turkbey, 2011, Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds, J Urol, 186, 1818, 10.1016/j.juro.2011.07.013 Vargas, 2016, Updated Prostate Imaging Reporting and Data System (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference, Eur Radiol, 26, 1606, 10.1007/s00330-015-4015-6 Le, 2015, Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: correlation with whole-mount histopathology, Eur Urol, 67, 569, 10.1016/j.eururo.2014.08.079 Sonn, 2017, Prostate magnetic resonance imaging interpretation varies substantially across radiologists, Eur Urol Focus Hansen, 2017, Comparison of initial and tertiary centre second opinion reads of multiparametric magnetic resonance imaging of the prostate prior to repeat biopsy, Eur Radiol, 27, 2259, 10.1007/s00330-016-4635-5 Kearns, 2018, Role of surveillance biopsy with no cancer as a prognostic marker for reclassification: results from the canary prostate active surveillance study, Eur Urol, 73, 706, 10.1016/j.eururo.2018.01.016 Bruinsma SM, Zhang L, Roobol MJ, et al. The Movember Foundation's GAP3 cohort: a profile of the largest global prostate cancer active surveillance database to date. BJU Int. In press. https://doi.org/10.1111/bju.14106.